Format

Send to

Choose Destination
J Cell Biochem. 2019 Apr;120(4):4804-4812. doi: 10.1002/jcb.28016. Epub 2018 Nov 2.

Optimization of prostate cancer cell detection using multiplex tyramide signal amplification.

Author information

1
The Johns Hopkins University, The Krieger School of Arts & Sciences, Baltimore, Maryland.
2
The James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
3
The Cellular and Molecular Medicine Program, Johns Hopkins School of Medicine, Baltimore, Maryland.

Abstract

Approximately 29 000 men die of prostate cancer (PCa) each year in the United States, and 90% to 100% of them are due to incurable bone metastasis. It is difficult to determine (1) when PCa disseminates in the natural history of the disease; (2) where cancer cell disseminates before becoming overt metastatic lesions; and (3) which tumors are aggressive and which are indolent. Tumor tissue and liquid (blood and bone marrow) biopsies provide important information to answer these questions, but significant limitations exist for immunostaining strategies that assess protein expression in these tissues. Classic immunohistochemistry (IHC) assays can typically assess expression of one or two proteins per tissue section. We have developed a novel immunofluorescence staining protocol to detect a panel of seven proteins on PCa tissue from primary tumor biopsies and metastatic lesion autopsy tissue, as well as cancer cells from liquid biopsies. We used a tyramide-based system to amplify the true signal and optimized the protocol to reduce background signal, thereby boosting the signal-to-noise ratio. Any protein-specific antibody in this protocol can be exchanged for a different validated antibody. This protocol therefore, represents a highly informative and flexible assay that can be used to provide important information about cancer tissue for the purpose of improving detection, diagnosis, and treatment.

KEYWORDS:

detection; immunofluorescence; metastasis; prostate cancer; tumor microarray; tyramide

PMID:
30390333
DOI:
10.1002/jcb.28016

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center